medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 2

<< Back Next >>

Med Int Mex 2021; 37 (2)

SARS-CoV-2 reinfection of health personnel in Mexico?

Jiménez-Saab NG, Uribe-Padilla G, Sánchez-Hernández G, Lira-Rivera L, Cabrera-Rayo A, López-Islas I, Rubio-Guerra AF

Language: Spanish
References: 24
Page: 212-220
PDF size: 420.77 Kb.


ABSTRACT

Objective: To communicate probable cases of COVID-19 reinfection in medical personnel.
Materials and Methods: A prospective, observational study performed from June to October 2020, in which information was collected on the cases of doctors who had COVID-19 reinfection.
Results: Twenty-four doctors with COVID-19 reinfection were included. The most frequent comorbidity in this group of cases was overweight or obesity in 15 patients (62%); 7 individuals did not report any comorbidity and 3 of the cases suffered from systemic arterial hypertension, of which 2 also had obesity.
Conclusions: The reinfection of COVID-19 is very likely and the SARS-CoV-2 virus does not provoke a perennial immunological memory in all infected individuals.


REFERENCES

  1. https://es.cochrane/es/recursos/evidencias-covid- 19/¿Cuál- es- el- riesgo- de- reinfección- por- coronavirus- sars- cov-2

  2. Bao L, Deng W, Gao X, Xiao C, et al. Reinfection could not occur in SARS-Cov 2 infectated Rhesus macaques. BioRxiv 2020 http://doi.org/10.1101/2020.03.13.990226.

  3. Ledford H. COVID 19 reinfection three questions scientists are asking. Nature 2020; 585 (10): 168-170.

  4. Tillett R, Servinsky J, Hartley P, Kerwin H, et al. Genomic evidence for reinfection with SARS-CoV 2: a case study. 2020. Lancet Infect Dis 2020. http://doi.org/10.1016/ S1473-3099(20)30764-7.

  5. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, et al. COVID 19 reinfection by phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America. SSRN 2020. https://doi.org/10.2139/ssrn.3686174.

  6. Van-Elslande J, Vermeersch P, Vandervoort K, Wawina- Bocalanga T, et al. Symptomatic SARS-CoV-2 reinfection by phylogenetically distinct strain. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa1275.

  7. Fan Wu, Wang A, Liu M, Wang Q, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 patient cohort and their implications. med Rxiv 2020; 03.30.20047365. doi. https://doi.org/10.1101/2020.03.30.20047365.

  8. López-Macías C, Rivera-Hernández T. Los anticuerpos y la protección contra COVID-19. Rev Med Inst Seguro Soc COVID-19 2020.

  9. Amnistía internacional 2020 https://amnistía.org .mx/ contenido/index.php/global-analisis-de-amnistia-internacional- revela-que-mas-de-7-mil-personas-trabajadoras-dela- salud-han-muerto-a-causa-de-covid-19/

  10. OPS. https://www.paho.org/es/noticias/2-9-2020-cerca- 570000-trabajadores-salud-se-han-infectado-2500-hanmuerto- por-covid-19.

  11. Ramírez S. En México el personal de salud muere seis veces más que en China por COVID-19. 16 de octubre de 2020. Mexicanos contra la corrupción y la impunidad. 2020. https://contralacorrupcion.mx/contagios-medicoscovid- 19/.

  12. López G, Ramírez M, Torres M. Participantes de la respuesta inmunológica ante la infección por SARS-CoV-2. Alergia Asma Inmunología Pediátricas 2020; 29 (1): 5-15. https:// dx.doi.org/10.35366/93321.

  13. Zhao J, Yuan Q, Wang H, Liu W, et al. Antibody responses to SARS CoV 2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; 71 (16): 2027-2034. doi. 10.1093/ cid/ciaa344.

  14. Xiao A, Gao C, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. J Infect 2020; 81 (1): 147-178. Doi. https:doi.org/10.1016/jinf 2020.03.012.

  15. Lu R, Zhao X, Li J, Niu P, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224): 565-574. doi. 10.1016/S0140-6736(20)30251-8.

  16. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int JBiol Sci 2020; 16: 1718-1723. doi.10.7150/ijbs.45123.

  17. Lin Q. Duration of serum neutralizing antibodies for SARSCoV- 2: Lesson from SARS-CoV infection. J Mycrobiology 2020; 53 (5): 821-822. doi. 10.1016/j.jmii.2020.03.015.

  18. Huang AT, Garcia Carrera B, et al. A systematic review of antibody mediated immunity to conoraviruses: antibody kinetics, correlates of protection and association of antibody responses with severity of diseases. med Rxiv 2020. https://doi.org/10.1101/2020.04.14.20065771.

  19. Nicasio M, Sauto G, Clementi N, Diotti RA, et al. Neutralization interfering antibodies: A “novel” example of humoral immune dysfunction facilitating viral escape? Viruses 2012; 4 (9): 1731-52. doi. 10.3390/v4091731.

  20. León-Delgado J, Pareja-Cruz A, Aguilar-Ramírez P, Enríquez- Valencia Y, et al. SARS-CoV-2 y sistema inmune: una batalla de titanes. Horiz Med (Lima) 2020; 20 (2): et1209.

  21. Pimienta-Bonifacio L, Sulino-Pereira AP, de Almeida-e Araujo DC, da Mata-Pasti Balbao V, et al. Are SARS-CoV-2 reinfection and Covid-19 recurrence possible? A case report from Brazil. Revista de Sociedade Brasileira de Medicina Tropical 2020; 53 (19). https://doi.org/10.1590/0037- 8682-0619-2020.

  22. Smith J. South Korea reports more recovered coronavirus patients testing positive again. Healthcare Pharma 2020. https://www.reuters.com/article/us-healthcoronavirussouthkorea/ south-korea-reports-more-recovered-coronaviruspatients- testing-positive-again-idUSKCN21V0JO.

  23. European Centre for Disease prevention and control, Reinfection with SARS -CoV2: consideration for public health response: ECDC; 2020.

  24. Abu-Raddad L, Chemaitelly H, Malek JA, Ahmed AA, et al Assessment of the risk of severe acute respiratory syndrome coronavirus (SARS-CoV-2) reinfection in an intense re-exposure setting. MedRxiv 2020. https://doi.org/10.11 01/2020.08.24.20179457.




2020     |     www.medigraphic.com